Pharming Group to participate in March investor conference
28 Fevereiro 2025 - 4:00AM
Leiden,
the Netherlands, February 28, 2025:
Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq:
PHAR) announces that Pharming’s management will participate in the
following investor conference in the month of March:
-
37th Annual Roth
Conference, Dana Point, CA, USA, March 16-18, 2025Anurag
Relan, Chief Medical Officer, and Michael Levitan, VP Investor
Relations and Corporate Communications, will participate in a
fireside chat question and answer session on Monday, March 17 at
01:30pm PT/21:30 CET.
For more information about this conference, or
to schedule a one-to-one meeting with Pharming’s management team,
please contact Pharming’s Investor Relations team at
investor@pharming.com or your Roth representative.
About Pharming Group
N.V.Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq:
PHAR) is a global biopharmaceutical company dedicated to
transforming the lives of patients with rare, debilitating, and
life-threatening diseases. Pharming is commercializing and
developing an innovative portfolio of protein replacement therapies
and precision medicines, including small molecules and biologics.
Pharming is headquartered in Leiden, the Netherlands, and has
employees around the globe who serve patients in over 30 markets in
North America, Europe, the Middle East, Africa, and
Asia-Pacific.
For more information, visit www.pharming.com and
find us on LinkedIn.
For further public information,
contact:Pharming Group, Leiden, the NetherlandsMichael
Levitan, VP Investor Relations & Corporate CommunicationsT: +1
(908) 705 1696E: investor@pharming.com
FTI Consulting, London, United KingdomSimon
Conway/Alex Shaw/Amy ByrneT: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam,
the NetherlandsLeon MelensT: +31 6 53 81 64 27E:
pharming@lifespring.nl
- Pharming attending Investor Conferences March
2025_EN_28FEB25
Pharming Group NV (EU:PHARM)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
Pharming Group NV (EU:PHARM)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025
